Targeted Factor Replacement is a therapeutic strategy in hematology that belongs to the class of treatment interventions for coagulation factor deficiencies, specifically characterized by the precise supplementation of deficient or dysfunctional clotting factors to restore hemostatic balance and prevent bleeding episodes.
30
Publications
3K
Citations
234
Authors
168
Institutions
Publications per year
2017–2026
10
Publications
30
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
Steven W. Pipe, Frank W.G. Leebeek, Michael Recht et al. · New England Journal of Medicine · 2023 · 343 citations · Full text
1–5 of 30
Authors
234
- JM
4
h-index
- GY
3
h-index
- MEMaria Elisa Mancuso
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Italy
3 publications · 1.3K citations
3
h-index
- VS
2
h-index
- MS
2
h-index
1–5 of 234
Institutions
168
University of North Carolina at Chapel Hill
Chapel Hill, United States
5 h-index
14 publications
1.3K citations
University of the Witwatersrand
Johannesburg, South Africa
4 h-index
4 publications
1.3K citations
Children's Hospital of Los Angeles
Los Angeles, United States
3 h-index
3 publications
855 citations
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
3 h-index
51 publications
23.9K citations
National Health Laboratory Service
Johannesburg, South Africa
3 h-index
3 publications
1.3K citations
Rush University Medical Center
Chicago, United States
3 h-index
3 publications
524 citations
University of California, Los Angeles
Los Angeles, United States
2 h-index
6 publications
234 citations
Baylor College of Medicine
Houston, United States
2 h-index
8 publications
214 citations
1–8 of 168
Venues
- Thrombosis and Haemostasis
4 publications · 365 citations
4
h-index
- New England Journal of Medicine
NEJM · 4 publications · 1.6K citations
4
h-index
- Blood
3 publications · 107 citations
3
h-index
- Haemophilia
3 publications · 128 citations
3
h-index
- The FASEB Journal
1 publications · 110 citations
1
h-index
1–5